NCT07789379
Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Progression-Free Survival (PFS)
Timeframe: From first study treatment, tumor imaging performed every 6-9 weeks (±7 days) for the first 24 weeks, then every 12 weeks (±7 days); assessed up to 24-months after first study treatment.
Secondary (4)
Overall Survival (OS)
Objective Response Rate (ORR)
Disease Control Rate (DCR)
hange from Baseline in Karnofsky Performance Status (KPS) score
Arms and interventions
Arm AExperimental
Adebrelimab + Temozolomide + Hyperbaric Oxygen Therapy
Arm BActive comparator
Adebrelimab + Temozolomide
Drugs: Adebrelimab, Temozolomide
Procedures: Procedure:Hyperbaric Oxygen Therapy